ライフサイエンスコーパス: a specificity of

1 iodontitis yielded a sensitivity of 0.91 and a specificity of 0.19.

2 a sensitivity of 0.72 (95% CI=0.67-0.76) and a specificity of 0.68 (95% CI=0.63-0.73).

3 One study reported a sensitivity of 0.82 and a specificity of 0.70 for 2 office-based blood pressure

4 (95% confidence interval [CI]: .87-.94) and a specificity of 0.71(95% CI: .68-.75) with an area unde

5 sensitivity of 0.90 (95% CI: 0.87-0.94) and a specificity of 0.71(95% CI: 0.68-0.75) with an area un

6 a sensitivity of 1.00 (95% CI 0.79-1.00) and a specificity of 0.78 (95% CI 0.69-0.85).

7 , that performed with a sensitivity of 0.91, a specificity of 0.79, a negative predictive value of 0.

8 5% confidence interval [CI]: 0.57, 0.94) and a specificity of 0.80 (95% CI: 0.66, 0.88).

9 d an AUC of 0.89, a sensitivity of 0.86, and a specificity of 0.82 in differentiating clinically diag

10 .0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative pre

11 myloid status with a sensitivity of 0.94 and a specificity of 0.83.

12 e a sensitivity of 0.70 (95% CI, 0.64-0.77), a specificity of 0.90 (95% CI, 0.84-0.93), a positive li

13 s a sensitivity of 0.69 (95% CI, 0.55-0.81), a specificity of 0.92 (95% CI, 0.86-0.95), a positive li

14 reached a sensitivity of 0.8758/0.9297, and a specificity of 0.9297/0.8758 for arteries/veins, respe

15 d sensitivity of 0.96 (95% CI 0.90-0.99) and a specificity of 0.95 (95% CI 0.92-0.96).

16 is presented with a sensitivity of 0.52 and a specificity of 0.95.

17 70 (CI(0) (.025) 0.53 to CI(0.975) 0.83) and a specificity of 0.97 (CI(0.025) 0.85 to CI(0.975) 0.99)

18 sensitivity of 0.468 (95% CI, 0.416-0.520), a specificity of 0.970 (95% CI, 0.955-0.981).

19 a subsequent rejection episode was 0.74 with a specificity of 0.99.

20 rquartile range [IQR], 0.9808 to 0.9904) and a specificity of 0.9954 (IQR, 0.9954 to 1.0).

21 involvement with a sensitivity of 0.875 and a specificity of 1.

22 d a sensitivity of 96% (23 of 24 lesions) at a specificity of 100% (23 of 23 lesions), yielding signi

23 The assay had a specificity of 100% (95% CI 98.9-100; 339 of 339 contr

24 87.3% (95% CI, 83.1 to 91.5%; n = 244), and a specificity of 100% (95% CI, 100 to 100; n = 201) on a

25 idence interval [CI], 90.26% to 100.00%) and a specificity of 100% (95% CI, 63.06% to 100.00%) when u

26 th a sensitivity of 67% (95% CI, 43-85%) and a specificity of 100% (95% CI, 78-100%).

27 a sensitivity of 77% (95% CI, 57 to 89) and a specificity of 100% (95% CI, 90 to 100).

28 sensitivity of 95% (95% CI, 83% to 99%) and a specificity of 100% (95% CI, 92% to 100%).

29 1%), respectively, while both assays display a specificity of 100% (95% CI, 92.5 to 100%).

30 ity of 90.91% (95% CI, 78.33% to 97.47%) and a specificity of 100% (95% CI, 93.40% to 100.00%) for th

31 ith a sensitivity of 48% (95% CI, 35-61) and a specificity of 100% (95% CI, 94-100).

32 5% confidence interval [CI], 3.3%-16.5%) and a specificity of 100% (95% CI, 96.2%-100%).

33 ularity in 21 of 94 lesions (P = .0006), for a specificity of 100% (95% confidence interval [CI]: 84,

34 criteria was 0% (95% CI, 0.0% to 0.5%), with a specificity of 100% (CI, 97% to 100%) and a positive p

35 nd a sensitivity of 75% (CI, 19% to 99%) and a specificity of 100% (CI, 97% to 100%) in the United Ki

36 on (sensitivity of 67% [16 of 24 lesions] at a specificity of 100% [23 of 23 lesions]) (P = .035).

37 nd 100% (23/23), respectively, while showing a specificity of 100% for each target.

38 llent; USG showed a sensitivity of 86.7% and a specificity of 100% for full-thickness tears, and a se

39 n general, HRCM had a sensitivity of 75% and a specificity of 100% in identifying recurrent or persis

40 merging the test results for all 3 antigens a specificity of 100% was achieved with a sensitivity of

41 ethods in screening 313 newborn babies, with a specificity of 100% with HemoTypeSC, 100% with SickleS

42 e population, a test sensitivity of 96%, and a specificity of 100%, the calculated VE estimates using

43 MTBDR-Plus had a sensitivity of 81.0% and a specificity of 100%, with sensitivities of 44.1% in AF

44 tion and copy number of inserted genes, with a specificity of 100%.

45 detecting surgery-related deaths of 33% and a specificity of 100%.

46 nor plasma specimens tested and demonstrated a specificity of 100%.

47 blood positive, for a sensitivity of 21% and a specificity of 100%.

48 ied as grade 2 with a sensitivity of 86% and a specificity of 100%.

49 -FDHT PET, yielding a sensitivity of 91% and a specificity of 100%; the optimal cutoff was an SUVmax

50 The graded PC had a specificity of 100.0% (95% CI, 90.9%-100.0%), a negati

51 confidence interval [CI], 66.1 to 99.8) and a specificity of 100.0% (95% CI, 98.4 to 100.0).

52 wine IAV-ss) with a sensitivity of 84.9% and a specificity of 100.0%.

53 95% confidence interval (CI): 57%, 97%]) and a specificity of 12 of 12 (100% [95% CI: 74%, 100%]) for

54 udy, the Canadian medium-risk rule exhibited a specificity of 12.3% (95% CI: 11.6%-13.1%), while the

55 a sensitivity of 99.2% (95% CI 95.4%-100%), a specificity of 20.8% (95% CI 19.2%-22.4%), and a negat

56 a sensitivity of 95.4% (95% CI 93.6%-96.9%), a specificity of 25.5% (95% CI 23.5%-27.5%), and a NPV o

57 a sensitivity of 99.2% (95% CI 95.4%-100%), a specificity of 31.7% (95% CI 29.9%-33.5%), and a NPV o

58 sitivity of 100% (95% CI: 96.7%-100.0%) with a specificity of 32.6% (95% CI: 31.5%-33.6%).

59 itivity of 100.0% (95% CI, 54.1%-100.0%) and a specificity of 33.3% (95% CI, 9.9%-65.1%).

60 11.6%-13.1%), while the NEXUS rule exhibited a specificity of 33.3% (95% CI: 32.3%-34.4%).

61 </=16 mg/mL showed a sensitivity of 87% and a specificity of 36%.

62 a sensitivity of 90.7% (95% CI 88.3%-92.8%), a specificity of 37.9% (95% CI 35.8%-40.1%), and a NPV o

63 With both S5 and cytology tests set at a specificity of 38.6% (95% CI 28.4-49.6) the sensitivit

64 h both the S5 classifier and cytology set at a specificity of 38.6% (95% confidence interval [CI], 28

65 ensitivity of 100% (95% CI, 63% to 100%) and a specificity of 40% (95% CI, 25% to 56%).

66 e measures displayed a sensitivity of 95.4%, a specificity of 40.1%, and positive and negative predic

67 /=16%) at baseline had a sensitivity of 88%, a specificity of 46%, and an accuracy of 0.67 (P<0.001)

68 a sensitivity of 89% (95% CI, 84 to 92), and a specificity of 47% (95% CI, 36 to 59).

69 a sensitivity of 88% (95% CI, 83 to 92), and a specificity of 47% (95% CI, 37 to 58).

70 e showed an overall sensitivity of 80.2% and a specificity of 47.1%, with positive and negative predi

71 hese symptoms had a sensitivity of 80.8% and a specificity of 51.2% for identifying a period in which

72 lts, the cobas test showed a sensitivity and a specificity of 51.9 and 86.6%, respectively.

73 95% confidence interval [CI], 64 to 89%) and a specificity of 52% (95% CI, 40 to 64%) at the manufact

74 tion genes and 87% for BRCA1 and BRCA2, with a specificity of 53%.

75 ad a sensitivity of 100% (29 of 29 lesions), a specificity of 53.2% (nine of 17 lesions), and an area

76 confidence interval [CI] = 60.7 to 93.5) and a specificity of 53.3% (95% CI = 37.9 to 68.3) for diagn

77 of 97.3% (95% CI: 92.3%-99.4%) and exhibited a specificity of 58.8% (95% CI: 57.7%-59.9%).

78 + 3 with a sensitivity of 93% (69%-99%) and a specificity of 62% (36%-82%).

79 criteria yielded a sensitivity of 71.4% and a specificity of 62.2%.

80 ADC measurement resulted in a specificity of 63%-64% and 61%-63%, sensitivity of 41%

81 95% confidence interval [CI], 93.6-98.6) and a specificity of 64% (95% CI, 61.6-66.4) for the diagnos

82 ) and </=75%TEI had a sensitivity of 98% but a specificity of 66% to predict viability at follow-up.

83 95% confidence interval [CI]: 72%-93%), with a specificity of 67% (95% CI: 45%-84%).

84 >= 4, which had a sensitivity of 78.36% and a specificity of 67.59%.

85 ith a sensitivity of 79% (95% CI, 64-94) and a specificity of 68% (95% CI, 56-80).

86 dict surgery with a sensitivity of 88.9% and a specificity of 69%.

87 cal biomarker, with a sensitivity of 97% and a specificity of 69%.

88 cut-off level of 432 pg/mL on day 1 yielded a specificity of 70% and a sensitivity of 64% for the pr

89 I, 0.666-0.847) and a sensitivity of 78% and a specificity of 70%, 3.51 mg/L was established as the l

90 Spot had an overall sensitivity of 89.8% and a specificity of 70.4%.

91 han or equal to 12 had a sensitivity of 90%, a specificity of 71%, a positive predictive value of 32%

92 to be detected with a sensitivity of 85% and a specificity of 71%.

93 )cum = 0.343) had a sensitivity of 76.0% and a specificity of 71.4% in the test group.

94 ensitivity, a negative predictive value, and a specificity of 71.4%, 87.5%, and 100%, respectively.

95 urine samples showed a sensitivity of 96.5%, a specificity of 71.4%, and positive and negative predic

96 ve yielded a sensitivity of 90% for OSA with a specificity of 71.4%.

97 ent (MCC) of 0.59, a sensitivity of 86%, and a specificity of 72% for FS indels.

98 [95% confidence interval]) 54% (44-63)% and a specificity of 73% (63-82)%.

99 , and 89%, respectively, for malignancy, and a specificity of 73%, 73%, 73%, 93%, and 60%, respective

100 ielded a sensitivity of 80% (95% CI: 51-95), a specificity of 74% (95% CI: 57-86), a PPV of 55% (95%

101 .5 ng/mL provided a sensitivity of 90.4% and a specificity of 74.1%.

102 shed with a sensitivity of 96% (79%-99%) and a specificity of 75% (30%-95%) for detecting a Gleason s

103 3 sensitization (sensitivity of 60%-63% and a specificity of 75%-67%, respectively).

104 nsitivity of 78.6% (95% CI, 60.5%-89.8%) and a specificity of 75.0% (95% CI, 55.1%-88.0%) for correct

105 Orbital CT had a sensitivity of 50.0% and a specificity of 75.0% to predict active TED using clini

106 redicted death with a sensitivity of 71% and a specificity of 76%.

107 sitivity of 85.1% (95% CI: 76.7%, 91.4%) and a specificity of 76.0% (95% CI: 71.2%, 80.2%).

108 ve delirium with a sensitivity of 71.19% and a specificity of 76.26% (receiver operating analysis, ar

109 50-5p expression had a sensitivity of 93.3%, a specificity of 76.5%, a positive predictive value of 7

110 3 (0.72-0.95), with a sensitivity of 85% and a specificity of 77% and was also superior to day 1 sept

111 e a sensitivity of 64% (95% CrI: 55, 73) and a specificity of 78% (95% CrI: 73, 83).

112 hours with a sensitivity of 57% and 70% and a specificity of 78% and 82%, respectively.

113 The model provides a specificity of 78% and negative predictive value of 73

114 mase-producing organisms (CPO), resulting in a specificity of 78% for the direct MAC plate method.

115 curacy of 74% (with a sensitivity of 68% and a specificity of 78%).

116 ned with a sensitivity of 78% (39 of 50) and a specificity of 79% (92 of 116).

117 to a sensitivity of 88% (95% CI: 87, 89) and a specificity of 79% (95% CI: 77, 80) by using a high-se

118 rse remodeling with a sensitivity of 84% and a specificity of 79%.

119 the AURKA gene copy number in urine yielded a specificity of 79.7% (95% confidence interval [CI] = 7

120 tivity of 90% (13 of 14; 95% CI: 88, 94) and a specificity of 80% (79 of 99; 95% CI: 76, 84).

121 um lytA rtPCR had a sensitivity of 78.1% and a specificity of 80.0%.

122 ensitivity of 80.3% (95% CI: 76.7-83.5%) and a specificity of 80.3% (95% CI: 76.9-83.3%).

123 sensitivity of 66.1% (95% CI 63.2-68.9) and a specificity of 80.6% (79.2-82.0) in the 12 months prec

124 itrary units had a sensitivity of 90.91% and a specificity of 80.60% for disseminated intravascular c

125 It had a sensitivity of 50% and a specificity of 81% for differentiating interstitial lu

126 5 identified 37.5% of eyes as progressing at a specificity of 81.1%.

127 nce of EEG-R for poor outcome prediction had a specificity of 82% and a sensitivity of 73%.

128 ons <50 nmol/L with a sensitivity of 61% and a specificity of 82%, whereas these values were 61% and

129 mear-negative, culture-positive samples with a specificity of 82%.

130 itivity of 71.4% (95% CI 30.3% to 94.9%) and a specificity of 82.0% (95% CI 72.1% to 89.1%) (cell-fre

131 as predicted with a sensitivity of 81.8% and a specificity of 82.4%.

132 with a sensitivity of 53.7% (42.6-64.3) and a specificity of 82.8% (76.7-86) in the 12 months preced

133 ensitivity of 80% and 55%, respectively, and a specificity of 83% and 63%.

134 versus no IA, with a sensitivity of 74% and a specificity of 83% at an optical density index cut-off

135 the baseline study had a sensitivity of 47%, a specificity of 83%, and an accuracy of 0.65 (P=0.002)

136 to predict CAV with a sensitivity of 72% and a specificity of 83%.

137 confidence interval [CI], 68.6 to 94.3) and a specificity of 83.6% (95% CI, 74.6 to 92.7) for the di

138 75-83%), and 55% (50-59%), respectively, and a specificity of 84% (81-87%), 64% (59-69%), and 70% (66

139 diagnostic of acute cellular rejection with a specificity of 84% and a sensitivity of 90%.

140 ssify the legions with a sensitivity of 96%, a specificity of 84%, and an AUC of 0.97.

141 take) resulted in a sensitivity of 81.3% and a specificity of 84.3%.

142 tivity of 71.4% and 70.4%, respectively, and a specificity of 84.6% and 80.3%, respectively.The respe

143 tivity of 72.9% and 63.2%, respectively, and a specificity of 84.7% and 85.3%, respectively; for ages

144 d a sensitivity of 49% (95% CI, 41%-57%) and a specificity of 85% (95% CI, 81%-89%) for predicting ch

145 gnosis of ABMR had a sensitivity of 100% and a specificity of 85%.

146 d 100% for LGI1-Ab-associated AE vs. hCSF at a specificity of 85%.

147 tion as recent with a sensitivity of 88% and a specificity of 85%.

148 confidence interval [CI]: 75.4%, 96.7%) and a specificity of 85.0% (95% CI: 74.9%, 91.7%).

149 sm criteria, with a sensitivity of 88.9% and a specificity of 85.7%, with several metabolites contrib

150 qPCR combined had a sensitivity of 100% and a specificity of 85.7%.

151 cted the results of the SARS-CoV-2 test with a specificity of 86.8%, a sensitivity of 82.4%, and an o

152 91% (95% CI: 77%, 98%; 32 of 35 wrists) and a specificity of 87% (95% CI: 60%, 98%; 53 of 60 wrists)

153 arted to discriminate from day 3 onward with a specificity of 87% and a sensitivity of 58% for a cut-

154 The results indicate a sensitivity of 40%, a specificity of 87%, precision of 57.8% and a measured

155 lation failure with a sensitivity of 82% and a specificity of 87%.

156 bapenemase producers (98% sensitivity), with a specificity of 87%.

157 sh RRMS with a sensitivity of 90.9% and with a specificity of 87.1% against AQP4-ab NMOSD, 95.2% agai

158 at a sensitivity of 97.6% (87.4%-99.9%) and a specificity of 87.5% (47.3%-99.7%).

159 trol animals with a sensitivity of 85.7% and a specificity of 87.5%, by gamma counter measurements.

160 f SCD with a sensitivity of 91% (78-98%) and a specificity of 88% (74-98%).

161 th a sensitivity of 90% (95% CI, 56-100) and a specificity of 88% (95% CI, 68-97).

162 5, 0.91-0.99), with a sensitivity of 93% and a specificity of 88%.

163 The testing set also revealed a specificity of 88%.

164 discriminate OIS patients from controls with a specificity of 88%.

165 participants with a sensitivity of 80.4% and a specificity of 88.0%, a finding that was confirmed usi

166 n the groups with a sensitivity of 90.0% and a specificity of 88.1%.

167 d a sensitivity of 93.1% (27 of 29 lesions), a specificity of 88.2% (15 of 17 lesions), and an area u

168 ed a sensitivity of 100% (29 of 29 lesions), a specificity of 88.2% (16 of 18 lesions), and an area u

169 d a sensitivity of 69.6% (62.1 to 76.4%) and a specificity of 88.4% (82.6 to 92.8%) during days 4 to

170 0.87-0.92)) with a sensitivity of 74.3% and a specificity of 88.4%.

171 ncreased to 78.1% using the custom slab with a specificity of 88.5%.

172 ence intervals [CI]: 84%, 96%; P < .001) and a specificity of 89% (95% CI: 81%, 94%; P < .001) for di

173 or a sensitivity of 78% (95% CI: 77, 79) and a specificity of 89% (95% CI: 88, 90) by using a high-sp

174 % (confidence interval [CI], 64% to 95%) and a specificity of 89% (CI, 73% to 97%) in Sierra Leone (n

175 % CI, 0.76-0.96), with a sensitivity of 73%, a specificity of 89%, a negative predictive value of 98%

176 -free outcomes with a sensitivity of 57% and a specificity of 89%.

177 8.3-96.4) and 94.3% (95% CI = 89.7-97.2) and a specificity of 89.1% (95% CI = 68.2-92.2) and 94.5% (9

178 f value of 3.25 ng/mL with a sensitivity and a specificity of 89.3% and 88.5%, respectively.

179 ntially methylated genes in T or OD produced a specificity of 89.4% and a sensitivity of 85.7%.

180 tration device had a sensitivity of 81.3% at a specificity of 90% (16 bladder cancer patients and 8 h

181 h a sensitivity of 100% (95% CI, 75-100) and a specificity of 90% (95% CI, 70-99).

182 s is predicted with a sensitivity of 84% and a specificity of 90%.

183 rve) of 0.81 with a sensitivity of 48% given a specificity of 90%.

184 gital software had a sensitivity of 100% and a specificity of 90.7% with the specificity ranging betw

185 ions was 0.913, with a sensitivity of 91.9%, a specificity of 90.7%, a positive predictive value (PPV

186 FCU yielded a specificity of 90.9% (95% confidence interval, 89.3-92

187 th an area under the curve of 0.97 +/- 0.04, a specificity of 91% (31 of 34), and a sensitivity of 94

188 ared with a sensitivity of 38% (18%-62%) and a specificity of 91% (76%-98%) for procalcitonin.

189 n Assessment Method for the ICU demonstrated a specificity of 91% (95% CI, 90-93), sensitivity of 75%

190 83% (95% confidence interval, 0.36-0.99) and a specificity of 91% (95% confidence interval, 0.77-0.97

191 of 0.295 provided a sensitivity of 89.5% and a specificity of 91.0% (AUC = 0.960; 95% CI 0.937-0.983)

192 ern (n = 172) showed a sensitivity of 71.6%, a specificity of 91.6%, and a positive predictive value

193 n a test set of 48 samples, for which it had a specificity of 92% (95% CI 81-100) and a sensitivity o

194 of>/=2 TIs yielded a sensitivity of 41% and a specificity of 92% for predicting ASD risk status, whe

195 m PAH samples with a sensitivity of 100% and a specificity of 92% in a randomly chosen validation set

196 ld be detected with a sensitivity of 99% and a specificity of 92% using a cutoff water content value

197 sensitivity of 93.9% (95% CI, 85.4%-97.6%), a specificity of 92.0% (95% CI, 85.9%-95.6%), a positive

198 an AUC of 0.81, a sensitivity of 54.3%, and a specificity of 92.4%.

199 tivity of 55.0% and 71.7%, respectively, and a specificity of 92.8% and 78.7% respectively; and for a

200 These data showed a sensitivity of 94.6% and a specificity of 92.9% for the above SD OCT features in

201 patients with CD and control subjects showed a specificity of 92.9%, which was higher than that of gl

202 CI: 44%, 83%) of MTM-HCCs (sensitivity) with a specificity of 93% (117 of 126; 95% CI: 87%, 97%).

203 80% (95% CI: 63%, 91%; 28 of 35 wrists) and a specificity of 93% (95% CI: 68%, 100%; 14 of 15 wrists

204 ensitivity of 80% and 93%, respectively, and a specificity of 93% and 93%, respectively.

205 At a specificity of 93%, our model had a higher sensitivity

206 tient validation, T2-weighted MR imaging had a specificity of 93%-97% and 87%-95%, sensitivity of 32%

207 follows: a sensitivity of 44.0% (80 of 182), a specificity of 93.1% (364 of 391), a positive predicti

208 tum present with a sensitivity of 93.36% and a specificity of 93.36%.

209 score of >=4 had a sensitivity of 30.4% and a specificity of 93.8%, whereas day 5 score of <=2 had a

210 sment and the FoCUS-assisted examination had a specificity of 94% (CI, 91% to 96%).

211 uence with an overall sensitivity of 91% and a specificity of 94% and (ii) predicts ptRNA-subclasses

212 Both cutoff points correspond with a specificity of 94% and represent sensitivity of 63% fo

213 The RAPDx had a sensitivity of 82% and a specificity of 94% for detection of RAPD whereas the b

214 ng at age 3 years with a sensitivity of 77%, a specificity of 94%, and an area under the curve (AUC)

215 ivity of 100.0% (95% CI, 98.0 to 100.0%) and a specificity of 94.0% (95% CI, 89.4 to 96.9%).

216 the M371 test showed a sensitivity of 90.1%, a specificity of 94.0%, an area under the curve of 0.966

217 was observed with a sensitivity of 92.9% and a specificity of 94.0%.

218 sitivity of 93.2% (95% CI: 88.9%, 97.1%) and a specificity of 94.2% (95% CI: 89.7%, 98.4%).

219 At a specificity of 94.3% (4 eyes showed ONH surface depres

220 he algorithm yielded a sensitivity of 94.5%, a specificity of 94.4%, a positive predictive value of 8

221 ase antibodies with a sensitivity of 50% and a specificity of 94.4%.

222 he algorithm yielded a sensitivity of 94.5%, a specificity of 94.5%, a positive predictive value of 8

223 he Direct LPA had a sensitivity of 88.4% and a specificity of 94.6% for M. tuberculosis detection, wi

224 itivity of 94.7% (95% CI, 73.5 to 99.9), and a specificity of 94.8% (95% CI, 88.9 to 97.8).

225 the TBI provided a sensitivity of 94.4% and a specificity of 94.9% (AUC = 0.988; 95% confidence inte

226 we obtained a sensitivity of 100% (5/5) and a specificity of 95% (58/61), caused by three false-posi

227 set of 36 samples, the RNAseq classifier had a specificity of 95% (84-100) and a sensitivity of 59% (

228 ols with a sensitivity of 88% (84%-95%), and a specificity of 95% (90%-100%).

229 positive PCR test results were found to have a specificity of 95% and a sensitivity of 64% for invasi

230 es were carried out, cut-offs selected using a specificity of 95% and seropositivity rates compared b

231 er the curve = 0.973; best cutoff point with a specificity of 95% representing a sensitivity of 96%).

232 AROC of 0.983 and a sensitivity of 96.7% at a specificity of 95%.

233 sensitivity of 51.4% (95% CI 38.5-64.2%) and a specificity of 95.4% (95% CI 90.7-97.8%) in women, and

234 was similar, with a sensitivity of 98.9% and a specificity of 95.5%.

235 the OPS-ELISA had a sensitivity of 71.6% and a specificity of 95.7% for Thai controls; for U.S. contr

236 ith a sensitivity of 56% (95% CI, 41-70) and a specificity of 96% (95% CI, 86-100).

237 CI: 80-93%) of post-diagnosis patients with a specificity of 96% (95% CI: 93-98%), We also demonstra

238 A score of >/= 4 for day 1 model had a specificity of 96% and sensitivity of 21%, whereas a s

239 V patient sera with a sensitivity of 91% and a specificity of 96% in the test set.

240 symptom onset with a sensitivity of 61% and a specificity of 96% using a cut-off of 0.34ng/ml.

241 The 90DM had a sensitivity of 74% and a specificity of 96%.

242 latness), reaching a sensitivity of 100% and a specificity of 96%.

243 latness), reaching a sensitivity of 100% and a specificity of 96%.

244 ic precision with a sensitivity of 77.7% and a specificity of 96.1%.

245 AMP subjects with ASD and is detectable with a specificity of 96.3% and a positive predictive value o

246 sitivity of 99.2% (range, 95.2% to 100%) and a specificity of 96.5% (range, 89.2% to 100%) for identi

247 y with a sensitivity of 93.5% (58 of 62) and a specificity of 96.6% (258 of 267).

248 confidence interval [CI], 88.2 to 96.2%) and a specificity of 96.7% (95% CI, 93.0 to 98.8%), and PCR-

249 nsitivity of 30.7% (95% CI, 18.9%-45.9%) and a specificity of 96.8% (95% CI, 94.2%-98.3%), with a par

250 selection yielded a sensitivity of 72.1% and a specificity of 96.9%.

251 SC)] with a sensitivity of 90% (73-98%) and a specificity of 97% (86-100%).

252 R assay had an overall sensitivity of 42.5%, a specificity of 97%, a positive predictive value of 77%

253 festation of all eight of these features has a specificity of 97%, and a sensitivity of 89% for the p

254 on of all three had a sensitivity of 99% and a specificity of 97%.

255 0% (95% confidence interval, 80% to 88%) and a specificity of 97.2% (95% confidence interval, 96% to

256 us ultrasound had a sensitivity of 88.4% and a specificity of 97.3% in detecting RD as compared with

257 nsitivity of 19.3% (95% CI, 12.0%-29.4%) and a specificity of 97.4% (95% CI, 95.2%-98.6%), with a par

258 ectional OCTA combined with en face OCTA had a specificity of 97.5% for grader A and 100% for grader

259 sitivity of 94.3% (range, 87.5% to 100%) and a specificity of 97.8% (range, 96.1% to 100%) for identi

260 The GeneChip showed a specificity of 97.8% and a sensitivity of 94.8% for de

261 an AUC of 0.90, a sensitivity of 63.0%, and a specificity of 97.8%.

262 f 69% (95% CI: 55%, 81%; 36 of 52 bones) and a specificity of 98% (95% CI: 97%, 99%; 682 of 696 bones

263 rker panel achieved a sensitivity of 85% and a specificity of 98%, with an area under the receiver op

264 th a sensitivity of 99.7% (98.3 to 100%) and a specificity of 98.0% (99.4 to 100%).

265 onstrated a sensitivity of 93.8% to 100% and a specificity of 98.0% to 100% for the identification of

266 credible interval [CrI], 77.4% to 86.7%) and a specificity of 98.1% (95% CrI, 97.2% to 100%) using pa

267 yielded an overall sensitivity of 97.4% and a specificity of 98.5%.

268 vity of 99.1% (95% CI: 95.13% to 99.98%) and a specificity of 98.6% (95% CI: 96.54% to 99.63%).

269 ckness tears, and a sensitivity of 89.7% and a specificity of 98.8% for partial-thickness tears; obse

270 Subanalysis yielded a specificity of 98.9% (95% CI, 98.3%-99.4%) for Candida

271 nce interval [CI], 94.5 to 99%; n = 244) and a specificity of 99% (95% CI, 97.8 to 100%; n = 292).

272 Adjusting thresholds to yield a specificity of 99%, 97%, or 93% resulted in almost equ

273 urve, IDO activity had a sensitivity of 97%, a specificity of 99%, and positive and negative predicti

274 The previously defined biomarker profile had a specificity of 99.0%, a sensitivity of 78.5%, and a po

275 r method achieved a sensitivity of 57.5% and a specificity of 99.2%, while maintaining a low FDR of 5

276 ng had a sensitivity of 97.0% (65 of 67) and a specificity of 99.4% (334 of 336).

277 sitivity of 99.6% (range, 96.4% to 100%) and a specificity of 99.5% (range, 98.0% to 100%) for identi

278 sitivity of 98.1% (range, 87.5% to 100%) and a specificity of 99.6% (range, 98.3% to 100%) for identi

279 esulting in a final sensitivity of 99.0% and a specificity of 99.6% for the detection of GAS in phary

280 was obtained with a sensitivity of 97.9% and a specificity of 99.6%.

281 ted with an overall sensitivity of 99.4% and a specificity of 99.7%.

282 2.6% (95% confidence interval, 88.8%-96.4%), a specificity of 99.8% (99.6%-99.9%), and a sensitivity

283 1.1% (95% confidence interval, 86.6%-95.5%), a specificity of 99.8% (99.7%-99.9%), and a sensitivity

284 ensitivity of 93.6% (95% CI 88.2%-97.0%) and a specificity of 99.9% (95% CI 99.6%-100%).

285 sensitivity of 100% (95% CI, 56.1%-100.0%), a specificity of 99.9% (95% CI, 99.9%-99.9%), a positive

286 hereas>/=4 TIs yielded a sensitivity of 19%, a specificity of 99.9%, and a positive likelihood ratio

287 tes and found one false positive, indicating a specificity of 99.90%.

288 ciently transduced serotonergic neurons with a specificity of approximately 95% in both mice and rats

289 entration for skin testing aiming to achieve a specificity of at least 95%.

290 rCor a 14 of 1 kUA/L or greater (adults) had a specificity of greater than 90% and accounted for 83%

291 d diagnose > 90% of IBH-affected horses with a specificity of > 95%.

292 All methods had a specificity of >90% for CROs, and for CPOs, the specif

293 compared to that of postmortem testing, with a specificity of >93.9%.

294 For good outcome prediction, a specificity of >=80% was used.

295 otocol, in particular DCE MR imaging, offers a specificity of more than 95% for distinguishing recurr

296 ing analogues of A to probe the basis for OG:A specificity of MutY.

297 ities of 98.4%-100%, while DNA detection had a specificity of only 77%.

298 ice compared with wild-type mice, indicating a specificity of soticlestat binding to CH24H.

299 This result implies a specificity of TMS at the dendritic level that could i

300 Furthermore, we uncovered a specificity of XRN function with regard to the directi